Lexology February 13, 2025
Ankura

The Centers for Medicare and Medicaid Services (CMS) recently announced the second cohort of Medicare Part D drugs selected for Maximum Fair Price negotiation (MFP) as part of the enhanced drug pricing authority granted to CMS by Congress through the Inflation Reduction Act (IRA). The MFPs for the 15 selected drugs will be determined over the next several months pursuant to the regulatory process established by CMS. MFPs for the current cohort will take effect on January 1, 2027, the initial price applicability year (IPAY) for these medicines. According to CMS, products were selected based on total gross covered prescription drug costs under Medicare Part D among other criteria set forth in the IRA.1

The new cohort reflects an increase...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, CMS, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
Related Articles:
The next wave: 2025 trends set to transform value-based care
Value-based payment models: Doctors describe the disconnect between theory and practice
How hospitals can prepare for CMS' new TEAM model
CMS suspends Hospice Special Focus Program
Prioritize Prior Authorization Reforms In Medicare Advantage

Share This Article